ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "clinical trials"

  • Abstract Number: 1868 • 2012 ACR/ARHP Annual Meeting

    Clinical Outcome in Fibromyalgia Patients Treated with Milnacipran Is Largely Independent of Symptom Duration

    Philip J. Mease1, Robert M. Bennett2, Robert H. Palmer3 and Yong Wang4, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Medicine & Nursing, Oregon Health & Science University, Portland, OR, 3Forest Research Institute, Inc., Jersey City, NJ, 4Forest Research Institute, Jersey City, NJ

    Background/Purpose: Patients with fibromyalgia (FM) usually experience pain, fatigue, and other debilitating symptoms for years. In clinical studies ranging from 3 months to >3 years,…
  • Abstract Number: 813 • 2012 ACR/ARHP Annual Meeting

    Rilonacept for Gout Flare Prophylaxis in Patients with Chronic Kidney Disease: Analysis of 3 Clinical Trials

    Robert Terkeltaub1, Robert R. Evans2, Steven P. Weinstein3, Richard Wu4 and H. Ralph Schumacher5, 1Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, 2Clinical Sciences, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 3Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 4BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 5Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA

    Background/Purpose: Gout flare (GF) prophylaxis in patients (pts) with chronic kidney disease (CKD; estimated glomerular filtration rate [eGFR]
  • Abstract Number: 1870 • 2012 ACR/ARHP Annual Meeting

    Financial Conflicts of Interest and Industry Sponsorship Are Associated with Positive Outcomes in Fibromyalgia Randomized Controlled Trials

    Winnie K. Pang1, Karen Yeter2, Nasim A. Khan3 and Karina D. Torralba1, 1Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, 2Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, 3Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR

    Background/Purpose: Fibromyalgia randomized controlled trials (RCTs) have become more common in the past 15 years, in part due to industry sponsorship. Recently, there has been…
  • Abstract Number: 818 • 2012 ACR/ARHP Annual Meeting

    Levotofisopam Has Uricosuric Activity and Reduces Serum Urate Levels in Patients with Gout

    Robert J. Noveck1, Zongyao Wang1, Ann Forsthoefel1, Kristina Sigmon2, Pauliana C. Hall3, John C. Keogh4 and John S. Sundy2, 1Duke Clinical Research Unit, Duke University Medical Center, Durham, NC, 2Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, 3PCH Integrated Regulatory Services, Inc., Laguna Niguel, CA, 4Keogh Medical Writing, Philadelphia, PA

    Background/Purpose: The investigational new drug levotofisopam is the S-enantiomer of racemic tofisopam, a 2,3-benzodiazepine derivative approved in over 20 countries outside the US for treatment…
  • Abstract Number: 1850 • 2012 ACR/ARHP Annual Meeting

    Association of Clinical Trial Characteristics with Positive Study Outcome Reporting in Randomized Controlled Trials of Rheumatoid Arthritis Therapy

    Fatima M. Khan1, Juan I. Lombeida2, Horace Spencer3, Karina D. Torralba4, Winnie K. Pang4 and Nasim A. Khan5, 1Rheumatology/Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 2Mercy Medical Center, Rogers, AR, 3University of Arkansas for Medical Sciences, Little Rock, AR, 4Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, 5Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR

    Background/Purpose: Randomized controlled trials (RCTs) are considered the best research design for assessing healthcare intervention. Concerns have been raised about the increased likelihood of positive…
  • Abstract Number: 831 • 2012 ACR/ARHP Annual Meeting

    A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab (AMG 827) in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate

    Karel Pavelka1, Yun Chon2, Richard Newmark2, Ngozi Erondu3 and Shao- Lee Lin2, 1Institute of Rheumatology and Department of Rheumatology, 1st Medical Faculty, Charles University Prague, Prague, Czech Republic, 2Clinical Development, Amgen Inc, Thousand Oaks, CA, 3Amgen Inc, Thousand Oaks, CA

    Background/Purpose: A potential role for IL-17 in rheumatoid arthritis (RA) has been supported by data from clinical studies of inhibitors of the IL-17A ligand. To…
  • Abstract Number: 1857 • 2012 ACR/ARHP Annual Meeting

    Identifying Core Symptom Domains in the Fibromyalgia Impact Questionnaire: Principal Component Analysis of Data From Milnacipran Clinical Studies

    Philip J. Mease1, Robert M. Bennett2, Robert H. Palmer3 and Yong Wang4, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Medicine & Nursing, Oregon Health & Science Univ, Portland, OR, 3Forest Research Institute, Inc., Jersey City, NJ, 4Forest Research Institute, Jersey City, NJ

    Background/Purpose: The Fibromyalgia Impact Questionnaire (FIQ) is a multidimensional instrument that encompasses many of the core domains recommended by OMERACT for evaluation in fibromyalgia (FM)…
  • Abstract Number: 755 • 2012 ACR/ARHP Annual Meeting

    Sifalimumab, an Anti-IFN-Alpha Monoclonal Antibody Shows Target Suppression of a Type I IFN Signature in Blood and Muscle of Dermatomyositis and Polymyositis Patients

    Brandon W. Higgs1, Wei Zhu2, Chris Morehouse1, Wendy White3, Philip Brohawn1, Charles Le4, Anthony A Amato5, David Fiorentino6, Steven A. Greenberg5, Laura Richman1, Warren Greth4, Bahija Jallal1 and Yihong Yao3, 1Translational Sciences, MedImmune, LLC, Gaithersburg, MD, 2Translational Science, MedImmune, LLC, Gaithersburg, MD, 3Translational Sciences, MedImmune, Gaithersburg, MD, 4Clinical Development, MedImmune, LLC, Gaithersburg, MD, 5Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 6Dermatology, Stanford University School of Medicine, Redwood City, CA

    Background/Purpose: To assess the pharmacodynamic effects of sifalimumab, an investigational anti-IFN-alpha monoclonal antibody, in the blood and muscle of adult dermatomyositis and polymyositis patients by…
  • Abstract Number: 1713 • 2012 ACR/ARHP Annual Meeting

    Developing an Index for Disease Activity and Therapeutic Response in Connective Tissue Disease Related Interstitial Lung Disease: Results From A Delphi Exercise: Delivering A Consensus On Domains

    Lesley Ann Saketkoo1, Dörte Huscher2, Dinesh Khanna3, Paul F. Dellaripa4, Kevin Flaherty5, Chester V. Oddis6, Kristine Phillips7, Athol U. Wells8, Christopher P. Denton9, Oliver Distler10, Otylia M. Kowal-Bielecka11, Romy Christmann12, Nora Sandorfi13, David Pittrow14, Vibeke Strand15, James R. Seibold16, Kevin K. Brown17 and Eric L. Matteson18, 1LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, 2German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, 3Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 4Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 5Department of Critical Care and Pulmonary Medicine, University of Michigan, Ann Arbor, MI, 6Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 7Rheumatology, University of Michigan, Ann Arbor, MI, 8Royal Brompton and Harefield NHS Foundation Trust, Department of Radiology, London, United Kingdom, 9Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, 10Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 11Department of Rheumatology and Internal Medicine, Medical University in Bialystok, Bialystok, Poland, 12Rheumatology, Boston University School of Medicine, Boston, MA, 13Division of Rheumatology, Thomas Jefferson Univ Med Coll, Philadelphia, PA, 14Institute of Clinical Pharmacology - University of Dresden, Dresden, Germany, 15Adjunct, Division of Immunology / Rheumatology, Stanford University, Portola Valley, CA, 16Scleroderma Research Consultants LLC, Avon, CT, 17Autoimmune Lung Center, National Jewish Hospital, Denver, CO, 18Rheumatology, Mayo Clinic, Rochester, MN

    Background/Purpose: Lack of reliable and valid measures of disease activity and clinical response in patients with connective tissue disease (CTD)-related interstitial lung disease (ILD) makes…
  • Abstract Number: 692 • 2012 ACR/ARHP Annual Meeting

    A Phase 1 Multicenter, Open-Label Study of MEDI-546, a Human Anti-Type I Interferon Receptor Monoclonal Antibody, in Adults with Scleroderma

    Avram Z. Goldberg1, Thomas D. Geppert2, Elena Schiopu3, Tracy M. Frech4, Vivien M. Hsu5, Robert W. Simms6, Stanford L. Peng7, Yihong Yao8, Nairouz Elgeioushi9, Bing Wang10, Linda Chang11 and Stephen Yoo12, 1Div of Rheumatology, North Shore-LIJ Health System, Lake Success, NY, 2Metroplex Clinical Research Center, LLC, Dallas, TX, 3Rheumatology/Internal Medicine, University of Michigan, Ann Arbor, MI, 4Internal Medicine-Division of Rheumatology, University of Utah School of Medicine, SLC, UT, 5Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, 6Rheumatology, Boston University School of Medicine, Boston, MA, 7Department of Rheumatology, Benaroya Research Institute at Virginia Mason Medical Center, Seattle, WA, 8Translational Sciences, MedImmune, Gaithersburg, MD, 9Medical Biostatistics, MedImmune, Gaithersburg, MD, 10Clinical Pharmacology and DMPK, Medimmune, Mountain View, CA, 11Translational Sciences, MedImmune, Hayward, CA, 12Clinical Development, MedImmune, Gaithersburg, MD

    Background/Purpose: Type I interferons (IFNs) have been implicated in the pathogenesis of scleroderma. This phase 1 study evaluated safety, pharmacokinetics (PK), pharmacodynamics, and immunogenicity of…
  • Abstract Number: 1594 • 2012 ACR/ARHP Annual Meeting

    Clinical and Radiological Outcomes After One Year of Remission Steered Combination Treatment in Patients with Early Rheumatoid and Undifferentiated Arthritis

    L. Heimans1, K.V.C. Wevers-de Boer1, K. Visser1, H.K. Ronday2, M. van Oosterhout3, J. H. L. M. Van Groenendael4, A.J. Peeters5, G. Steup-Beekman6, G. Collee7, P.B.J Sonnaville8, B.A. Grillet9, Tom Huizinga1 and C.F. Allaart1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Haga Hospital, The Hague, Netherlands, 3Rheumatology, Groene Hart Hospital, Gouda, Netherlands, 4Franciscus Hospital, Roosendaal, Netherlands, 5Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, 6Rheumatology, Bronovo Hospital, Netherlands, 7MCH, The Hague, Netherlands, 8Admiraal de Ruyter Ziekenhuis, Goes, Netherlands, 9Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands

    Background/Purpose: To evaluate the 1 year clinical and radiological outcomes of remission steered therapy in early arthritis patients treated aiming at remission (DAS
  • Abstract Number: 360 • 2012 ACR/ARHP Annual Meeting

    Initial Introduction of Treat-to-Target Strategy in Patients with Recent Onset Rheumatoid Arthritis Is More Effective Than Delayed Introduction of Strategy with More Clinical and Functional Remission Achieved for 2-Years: Results of the Treating to Twine Targets (T-4) Study

    Yukitomo Urata1, Yoshihide Nakamura2 and Ken-ichi Furukawa3, 1Rheumatology, Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, 2Orthopaedic Surgery, Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, 3Pharmacology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan

    Background/Purpose: To compare the clinical, radiological and functional efficacy of initial versus delayed introduction of strategy which is treat-to-target to patients with recent onset rheumatoid…
  • Abstract Number: 1320 • 2012 ACR/ARHP Annual Meeting

    Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Effects On Hemoglobin Levels in a Clinical Trial for the Treatment of Moderate-to-Severe Rheumatoid Arthritis

    Mark C. Genovese1, Roy Fleischmann2, Martine Jasson3, Allen R. Radin4, Jennifer Hamilton5 and Tom W.J. Huizinga6, 1Division of Rheumatology, Stanford University, Palo Alto, CA, 2Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, 3Clinical Development, Sanofi-Aventis, Paris, France, 4Translational Medicine, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 5Predictive Medicine, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 6Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Anemia of chronic disease, a common extra-articular manifestation of rheumatoid arthritis (RA), which has a substantial impact on patient function, is driven in part…
  • Abstract Number: 257 • 2012 ACR/ARHP Annual Meeting

    Meta-Analysis of Four 12-Week Phase III Clinical Trials Investigating the Effect of TDT 064, a Transdermal Gel, in Osteoarthritis of the Knee

    Matthias Rother1, Johannes C. Vester2, Wolfgang W. Bolten3 and Philip G. Conaghan4, 1IMR Partner GmbH, Graefelfing, Germany, 2IDV Data Analysis and Study Planning, Krailling, Germany, 3Rheumatology, Klaus-Miehlke-Klink, Wiesbaden, Germany, 4University of Leeds, Leeds, United Kingdom

    Background/Purpose: A transfersome is an ultradeformable lipid vesicle originally developed to deliver high concentrations of drug (eg NSAIDs) transdermally. Large interventional trials in osteoarthritis (OA)…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology